The phase II Eagle trial is a randomized, open-label and multi-centre trial designed to assess Imfinzi monotherapy and Imfinzi in combination with anti-CTLA4 antibody tremelimumab against SoC chemotherapy
The Transaction has been unanimously approved by the Board of Directors of each company. Subject to potential adjustment as described below, based upon an OncoMed net cash balance
UCB will build a new £150mto £200m research and development facility as part of the total investment over the next five years. The transition to the facility will
Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has
The phase 3 MAIA study showed that the daratumumab, in combination with lenalidomide and dexamethasone (Rd), has reduced the risk of disease progression or death in patients with
The companies have entered into a collaboration and license agreement for TR009 (formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic
Based in Waltham of Massachusetts, Tesaro is a commercial-stage firm engaged in the development of advanced therapies to treat cancer. As per the terms of the deal, GSK’s
GSK’s consumer healthcare portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and
RXC006 is being developed as an orally administered and first-in-class treatment for the orphan disease idiopathic pulmonary fibrosis (IPF), which is a chronic lung condition. RXC006, which is
Gilenya is claimed to be the first and only oral disease-modifying treatment approved for children and adolescents in the Europe. The approval allows the company to market Gilenya
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.